A BILL FOR AN ACT

RELATING TO ELECTRONIC PRESCRIPTIONS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1. On March 31, 2010, the Drug Enforcement
2	Administration published in the Federal Register its rule
3	"Electronic Prescriptions for Controlled Substances", which
4	became effective on June 1, 2010, and which revises the Drug
5	Enforcement Administration's regulations to provide
6	practitioners with the option of writing prescriptions for
7	controlled substances electronically. The regulations also
8	permit pharmacies to receive, dispense, and archive these
9	electronic prescriptions for controlled substances. These new
10	regulations do not mandate that practitioners prescribe
11	controlled substances using only electronic prescriptions nor do
12	these new regulations require pharmacies to accept only
13	electronic prescriptions for controlled substances for

dispensing. The use of electronic prescriptions for controlled

pharmacies. Electronic prescriptions for controlled substances

substances is voluntary on the part of the practitioners and

may be conveyed electronically; provided that the electronic

14

15

16

17

- 1 prescription and the pharmacy application meet the Drug
- 2 Enforcement Administration's and state's requirements.
- 3 Practitioners are still able to write and must manually
- 4 sign prescriptions for controlled substances in Schedule II,
- 5 III, IV, and V and may convey valid written prescriptions for
- 6 controlled substances via facsimile to pharmacies for Schedule
- 7 III, IV, and V. Orally-ordered prescriptions remain valid for
- 8 Schedule III, IV, and V and under emergency provisions for
- 9 Schedule II prescriptions.
- 10 By allowing practitioners to electronically prescribe
- 11 controlled substances and to convey the prescription directly to
- 12 the pharmacy of the patient's choice, it will provide
- 13 practitioners with a safer, more secure, and timely means to
- 14 prescribe controlled substances in addition to the conventional
- 15 means of prescribing controlled substances.
- 16 The purpose of this Act is to amend the Uniform Controlled
- 17 Substances Act in chapter 329, Hawaii Revised Statutes, by:
- 18 (1) Adding definitions to section 329-1, Hawaii Revised
- 19 Statutes, to be consistent with federal law;
- 20 (2) Clarifying the conditions for the transmittal of
- 21 prescriptions electronically; and



1 (3) Adding and clarifying new violations of prohibited 2 acts. SECTION 2. Section 329-1, Hawaii Revised Statutes, is 3 amended by adding three new definitions to be appropriately 4 5 inserted and to read as follows: 6 ""Electronic prescription" means a prescription that is 7 generated on an electronic prescription application and 8 transmitted as an electronic data file that complies with all 9 applicable requirements of Title 21 Code of Federal Regulations 10 Part 1311 and any additional rules adopted by the department. 11 "Electronic prescription application" means electronic 12 prescription software either as a stand-alone application or as a module in an electronic health record application. 13 14 "Electronic signature" means a method of signing an 15 electronic message that identifies a particular person as the source of the message and indicates the person's approval of the 16 information contained in the message." **17** SECTION 3. Section 329-38, Hawaii Revised Statutes, is 18 19 amended to read as follows: "§329-38 Prescriptions. (a) No controlled substance in 20 21 schedule II may be dispensed without a written prescription of a

HB HMS 2013-1299

22



practitioner, except:

1	(1)	In t	the case of an emergency situation, a pharmacist		
2		may	dispense a controlled substance listed in schedule		
3		II u	II upon receiving oral authorization from a		
4		pres	cribing practitioner; provided that:		
5		(A)	The quantity prescribed and dispensed is limited		
6			to the amount adequate to treat the patient		
7			during the emergency period (dispensing beyond		
8			the emergency period must be pursuant to a		
9			written prescription signed by the prescribing		
10			practitioner);		
11		(B)	If the prescribing practitioner is not known to		
12			the pharmacist, the pharmacist shall make a		
13			reasonable effort to determine that the oral		
14			authorization came from a registered		
15			practitioner, which may include a callback to the		
16			prescribing practitioner using the phone number		
17		÷	in the telephone directory or other good faith		
18			efforts to identify the prescriber; and		
19		(C)	Within seven days after authorizing an emergency		
20			oral prescription, the prescribing practitioner		
21			shall cause a written prescription for the		
22			emergency quantity prescribed to be delivered to		

1	the dispensing pharmacist. In addition to
2	conforming to the requirements of this
3	subsection, the prescription shall have written
4	on its face "Authorization for Emergency
5	Dispensing". The written prescription may be
6	delivered to the pharmacist in person or by mail,
7	and if by mail, the prescription shall be
8	postmarked within the seven-day period. Upon
9	receipt, the dispensing pharmacist shall attach
10	this prescription to the oral emergency
11	prescription, which had earlier been reduced to
12	writing. The pharmacist shall notify the
13	administrator if the prescribing practitioner
14	fails to deliver a written prescription to the
15	pharmacy within the allotted time. Failure of
16	the pharmacist to do so shall void the authority
17	conferred by this paragraph to dispense without a
18	written prescription of a prescribing individual
19	practitioner. Any practitioner who fails to
20	deliver a written prescription within the seven-
21	day period shall be in violation of section 329-
22	41(a)(1); [or]

1	(2)	When dispensed directly by a practitioner, other than
2		a pharmacist, to the ultimate user. The practitioner
3		in dispensing a controlled substance in schedule II
4		shall affix to the package a label showing:
5		(A) The date of dispensing;
6		(B) The name, strength, and quantity of the drug
7		dispensed;
8		(C) The dispensing practitioner's name and address;
9		(D) The name of the patient;
10		(E) The "use by" date for the drug, which shall be:
11		(i) The expiration date on the
12		[{]manufacturer's[}] or principal labeler's
13		container; or
14		(ii) One year from the date the drug is
15		dispensed, whichever is earlier; and
16		(F) Directions for use, and cautionary statements, if
17		any, contained in the prescription or as required
18		by law.
19		A complete and accurate record of all schedule II
20		controlled substances ordered, administered,
21		prescribed, and dispensed shall be maintained for five
22		years. Prescriptions and records of dispensing shall

НВ HMS 2013-1299

1		otherwise be retained in conformance with the
2		requirements of section 329-36. No prescription for a
3		controlled substance in schedule II may be
4		refilled[→]; or
5	<u>(3)</u>	In the case of an electronic prescription, a
6		pharmacist may dispense a controlled substance listed
7		in schedule II upon receiving an electronic
8		prescription.
9	(d)	A schedule II controlled substance prescription shall:
10	(1)	Be filled within seven days following the date the
11		prescription was issued to the patient; and
12	(2)	Be supplied to a patient only if the prescription has
13		been filled and held by the pharmacy for not more than
14		seven days.
15	(c)	The transfer of original prescription information for a
16	controlle	d substance listed in schedule III, IV, or V for the
17	purpose o	f dispensing is permissible between pharmacies on a one
18	time basi	s only. However, pharmacies electronically sharing a
19	real-time	, online database may transfer up to the maximum
20	refills p	ermitted by law and the prescriber's authorization.
21	Transfers	are subject to the following requirements:

HB HMS 2013-1299

1	(1)	The t	cransfer shall be communicated directly between
2		two 2	licensed pharmacists, and the transferring
3		pharm	nacist shall:
4		(A)	Write or otherwise place the word "VOID" on the
5			face of the invalidated prescription;
6		(B)	Record on the reverse of the invalidated
7			prescription the name, address, and [DEA] Drug
8			Enforcement Administration registration number of
9			the pharmacy to which it was transferred and the
10			name of the pharmacist receiving the prescription
11			information; and
12		(C)	Record the date of the transfer and the name of
13			the pharmacist transferring the information;
14	(2)	The p	pharmacist receiving the transferred prescription
15		info	rmation shall reduce to writing the following:
16		(A)	Write or otherwise place the word "transfer" on
17			the face of the transferred prescription;
18		(B)	Record all information required to be on a
19			prescription, including:
20			(i) The date of issuance of original
21	i		prescription;

1		(ii)	The original number of refills authorized on
2			original prescription;
3		(iii)	The date of original dispensing;
4		(iv)	The number of valid refills remaining and
5			dates and locations of previous refills;
6		(v)	The pharmacy's name, address, [DEA] Drug
7			Enforcement Administration registration
8			number, and original prescription number
9			from which the prescription information was
10			transferred;
11		(vi)	The name of $\underline{\text{the}}$ transferor pharmacist; and
12		(vii)	The pharmacy's name, address, and Drug
13			Enforcement Administration registration
14			number, along with the prescription number
15			from which the prescription was originally
16			filled;
17	(3)	Both the	original and transferred prescription shall
18		be mainta	ined for a period of five years from the date
19		of last r	refill; and
20	(4)	Any pharm	acy electronically accessing a prescription
21		record sh	all satisfy all information requirements of a
22		manual mo	ode prescription transferal.

нв нмs 2013-1299

1	. Failure to	o comply with this subsection shall void the
2	authority of th	he pharmacy to transfer prescriptions or receive a
3	transferred pro	escription to or from another pharmacy.
4	(d) A ph	armacy and an authorized central fill pharmacy may
5	share informat	ion for initial and refill prescriptions of
6	schedule III,	IV, or V controlled substances. The following
7	requirements sl	nall apply:
8	(1) A ph	armacy may electronically transmit, including by
9	facs	imile, prescriptions for controlled substances
10	liste	ed in schedule III, IV, or V to a central fill
11	phari	macy. The pharmacy transmitting the prescription
12	info	rmation shall:
13	(A)	Ensure that all information required to be on a
14		prescription pursuant to subsection (g) is
15		transmitted to the central fill pharmacy either
16		on the face of the prescription or
17	·	electronically; and
18	(B)	Keep a record of receipt of the filled
19		prescription, including the date of receipt, the
20		method of delivery (private, common, or contract
21		carrier) and the identity of the pharmacy
22		employee accepting delivery; and

1	(2)	The	central fill pharmacy receiving the transmitted
2		pres	cription shall:
3		(A)	Keep for five years a copy of a prescription
4			received by facsimile or an electronic record of
5			all the information transmitted by the pharmacy,
6			including the name, address, and [DEA] Drug
7			Enforcement Administration registration number of
8			the pharmacy transmitting the prescription;
9		(B)	Keep a record of the date of receipt of the
10			transmitted prescription, the name of the
11			licensed pharmacists filling the prescription,
12			and the dates the prescription was filled or is
13			refilled; and
14		(C)	Keep a record of the date the filled prescription
15			was shipped to the pharmacy.
16	(e)	No c	ontrolled substance in schedule III, IV, or V may
17	be dispen	sed w	ithout a written, facsimile of a written, [or]
18	oral pres	cript	ion of a practitioner, or receipt of an electronic
19	prescript	ion,	except when a controlled substance is dispensed
20	directly 1	by a	practitioner, other than a pharmacist, to an
21	ultimate	user.	The practitioner, in dispensing a controlled

1 substance in schedule III, IV, or V, shall affix to the package 2 a label showing: 3 (1)The date of dispensing; 4 (2)The name, strength, and quantity issued of the drug; 5 (3)The dispensing practitioner's name and business 6 address; 7 (4)The name of the patient; 8 (5) The "use by" date for the drug, which shall be: 9 The expiration date on the manufacturer's or (A) **10** principal labeler's container; or 11 One year from the date the drug is dispensed, (B) 12 whichever is earlier; 13 Directions for use; and (6) 14 Cautionary statements, if any, contained in the (7) 15 prescription or as required by law. 16 A complete and accurate record of all schedule III, IV, and V 17 controlled substances administered, prescribed, and dispensed 18 shall be maintained for five years. Prescriptions and records 19 of dispensing shall be retained in conformance with the 20 requirements of section 329-36 unless otherwise provided by law. 21 Prescriptions may not be filled or refilled more than three 22 months after the date of the prescription or be refilled more HB HMS 2013-1299

5

10

13

16

H.B. NO. 651

1 than two times after the date of the prescription, unless the

2 prescription is renewed by the practitioner.

3 (f) The effectiveness of a prescription for the purposes

4 of this section shall be determined as follows:

(1) A prescription for a controlled substance shall be

6 issued for a legitimate medical purpose by an

7 individual practitioner acting in the usual course of

8 the practitioner's professional practice. The

9 responsibility for the proper prescribing and

dispensing of controlled substances shall be upon the

11 prescribing practitioner, but a corresponding

responsibility shall rest with the pharmacist who

fills the prescription. An order purporting to be a

14 prescription issued not in the usual course of

15 professional treatment or for legitimate and

authorized research shall not be deemed a prescription

within the meaning and intent of this section, and the

18 person who knowingly fills such a purported

19 prescription, as well as the person who issues the

20 prescription, shall be subject to the penalties

21 provided for violations of this chapter;

ӉВ HMS 2013-1299

1	(2)	A prescription may not be issued to allow an
2		individual practitioner to obtain controlled
3		substances for supplying the individual practitioner
4		for the purpose of general dispensing to patients;
5	(3)	A prescription may not be issued for the dispensing of
6		narcotic drugs listed in any schedule for the purpose
7		of "detoxification treatment" or "maintenance
8		treatment" except as follows:
9		(A) The administering or dispensing directly (but not
10		prescribing) of narcotic drugs listed in any
11		schedule to a narcotic drug-dependent person for
12		"detoxification treatment" or "maintenance
13		treatment" shall be deemed to be "in the course
14		of a practitioner's professional practice or
15		research" so long as the practitioner is
16		registered separately with the department and the
17		federal Drug Enforcement Agency as required by
18		section 329-32(e) and complies with Title 21 Code
19		of Federal Regulations section 823(g) and any

other federal or state regulatory standards

records, and unsupervised use of drugs; and

relating to treatment qualification, security,

20

21

22

1		(B) Nothing in this section shall prohibit a
2		physician or authorized hospital staff from
3		administering or dispensing, but not prescribing
4		narcotic drugs in a hospital to maintain or
5		detoxify a person as an incidental adjunct to
6		medical or surgical treatment of conditions othe
7		than addiction;
8	(4)	An individual practitioner shall not prescribe or
9		dispense a substance included in schedule II, III, IV
10		or V for that individual practitioner's personal use,
11		except in a medical emergency; and
12	(5)	A pharmacist shall not dispense a substance included
13		in schedule II, III, IV, or V for the pharmacist's
14		personal use.
15	(g)	Prescriptions for controlled substances shall be
16	issued on	ly as follows:
17	(1)	All prescriptions for controlled substances shall
18		originate from within the State and be dated as of,
19		and signed on, the day when the prescriptions were
20		issued and shall contain:
21		(A) The first and last name and address of the
22		patient; and

нв нмs 2013-1299

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

H.B. NO. 651

1 (B) The drug name, strength, dosage form, quantity
2 prescribed, and directions for use. Where a
3 prescription is for gamma hydroxybutyric acid,
4 methadone, or buprenorphine, the practitioner
5 shall record as part of the directions for use,
6 the medical need of the patient for the
7 prescription.

[The] Except for electronic prescriptions, controlled substance prescriptions shall be no larger than eight and one-half inches by eleven inches and no smaller than three inches by four inches. A practitioner may sign a prescription in the same manner as the practitioner would sign a check or legal document (e.g., J.H. Smith or John H. Smith) and shall use both words and figures (e.g., alphabetically and numerically as indications of quantity, such as five (5)), to indicate the amount of controlled substance to be dispensed. Where an oral order or electronic prescription is not permitted, prescriptions shall be written with ink or indelible pencil or typed, shall be manually signed by the practitioner, and shall include the name, address, telephone number, and

H.B. NO. 651

1	registration number of the practitioner. The
2	prescriptions may be prepared by a secretary or agent
3	for the signature of the practitioner, but the
4	prescribing practitioner shall be responsible in case
5	the prescription does not conform in all essential
6	respects to this chapter and any rules adopted
7	pursuant to this chapter. In receiving an oral
8	prescription from a practitioner, a pharmacist shall
9	promptly reduce the oral prescription to writing,
10	which shall include the following information: the
11	drug name, strength, dosage form, quantity prescribed
12	in figures only, and directions for use; the date the
13	oral prescription was received; the full name, [DEA]
14	<u>Drug Enforcement Administration</u> registration number,
15	and oral code number of the practitioner; and the name
16	and address of the person for whom the controlled
17	substance was prescribed or the name of the owner of
18	the animal for which the controlled substance was
19	prescribed.
20	A corresponding liability shall rest upon a

pharmacist who fills a prescription not prepared in the form prescribed by this section. A pharmacist may



1		add a patient's missing address or change a patient's
2		address on all controlled substance prescriptions
3		after verifying the patient's identification and
4		noting the identification number on the back of the
5		prescription[-] document on file. The pharmacist
6		shall not make changes to the patient's name, the
7		controlled substance being prescribed, the quantity of
8		the prescription, the practitioner's [DEA] Drug
9		Enforcement Administration number, the practitioner's
10		name, the practitioner's electronic signature, or the
11		practitioner's signature;
12	(2)	An intern, resident, or foreign-trained physician, or
13		a physician on the staff of a Department of Veterans
14		Affairs facility or other facility serving veterans,
15		exempted from registration under this chapter, shall
16		include on all prescriptions issued by the physician:
17		(A) The registration number of the hospital or other
18		institution; and
19		(B) The special internal code number assigned to the
20		physician by the hospital or other institution in
21		lieu of the registration number of the
22		practitioner required by this section.

1		The hospital of other institution shall forward a copy
2		of this special internal code number list to the
3		department as often as necessary to update the
4		department with any additions or deletions. Failure
5		to comply with this paragraph shall result in the
6		suspension of that facility's privilege to fill
7		controlled substance prescriptions at pharmacies
8		outside of the hospital or other institution. Each
9		written prescription shall have the name of the
10		physician stamped, typed, or hand-printed on it, as
11		well as the signature of the physician;
12	(3)	An official exempted from registration shall include
13		on all prescriptions issued by the official:
14		(A) The official's branch of service or agency (e.g.,
15		"U.S. Army" or "Public Health Service"); and
16		(B) The official's service identification number, in
17		lieu of the registration number of the
18		practitioner required by this section. The
19		service identification number for a Public Health
20		Service employee shall be the employee's social
21		security or other government issued
22		identification number.

1		Each prescription shall have the name of the officer
2		stamped, typed, or handprinted on it, as well as the
3		signature of the officer; and
4	(4)	A physician assistant registered to prescribe
5	•	controlled substances under the authorization of a
6		supervising physician shall include on all controlled
7		substance prescriptions issued:
8		(A) The [DEA] Drug Enforcement Administration
9		registration number of the supervising physician
10		and
11		(B) The [DEA] Drug Enforcement Administration
12		registration number of the physician assistant.
13		Each written controlled substance prescription issued
14		shall include the printed, stamped, typed, or hand-
15		printed name, address, and phone number of both the
16		supervising physician and physician assistant, and
17		shall be signed by the physician assistant. The
18		medical record of each written controlled substance
19		prescription issued by a physician assistant shall be
20		reviewed and initialed by the physician assistant's
21	-	supervising physician within seven working days.

1

H.B. NO. 651

2	filled by a pharmacist acting in the usual course of the
3	pharmacist's professional practice and either registered
4	individually or employed in a registered pharmacy, central fill
5	pharmacy, or registered institutional practitioner. A central
6	fill pharmacy authorized to fill prescriptions on behalf of a
7	pharmacy shall have a contractual relationship with the pharmacy
8	that provides for this activity or shall share a common owner
9	with the pharmacy. A central fill pharmacy shall not prepare
10	prescriptions for any controlled substance listed in schedule
11	II.
12	(i) Partial filling of controlled substance prescriptions
13	shall be determined as follows:
14	(1) The partial filling of a prescription for a controlled
15	substance listed in schedule II is permissible if the
16	pharmacist is unable to supply the full quantity
17	called for in a written, electronic prescription, or
18	emergency oral prescription and the pharmacist makes a
19	notation of the quantity supplied on the face of the
20	written prescription (or written record of the
21	electronic prescription or emergency oral
22	prescription). The remaining portion of the

(h) A prescription for controlled substances may only be

нв нмs 2013-1299

1		pres	cription may be filled within seventy-two hours of
2		the	first partial filling; provided that if the
3		rema	ining portion is not or cannot be filled within
4		the	seventy-two-hour period, the pharmacist shall
5		noti	fy the prescribing individual practitioner. No
6		furt	her quantity shall be supplied beyond seventy-two
7		hour	s without a new prescription;
8	(2)	The	partial filling of a prescription for a controlled
9		subs	tance listed in schedule III, IV, or V is
10		perm	issible; provided that:
11		(A)	Each partial filling is recorded in the same
12			manner as a refilling;
13		(B)	The total quantity dispensed in all partial
14	•		fillings does not exceed the total quantity
15			prescribed;
16		(C)	No dispensing occurs more than three months after
17			the date on which the prescription was issued;
18			and
19		(D)	The prescription is refilled no more than two
20			times after the initial date of the prescription,
21			unless the prescription is renewed by the
22			practitioner; and

HB HMS 2013-1299

H.B. NO. WSI

1	(3)	A prescription for a schedule II controlled substance
2		[written] issued for a patient in a long-term care
3		facility or for a patient with a medical diagnosis
4		documenting a terminal illness may be filled in
5		partial quantities to include individual dosage units
6		If there is any question whether a patient may be
7		classified as having a terminal illness, the
8		pharmacist shall contact the practitioner prior to
9		partially filling the prescription. Both the
10		pharmacist and the prescribing practitioner have a
11		corresponding responsibility to assure that the
12		controlled substance is for a terminally ill patient.
13		The pharmacist shall record on the prescription
14		document on file whether the patient is "terminally
15		ill" or a "long-term care facility patient". For the
16		purposes of this section, "TI" means terminally ill
17		and "LTCF" means long-term care facility. A
18		prescription that is partially filled and does not
19		contain the notation "TI" or "LTCF patient" shall be
20		deemed to have been filled in violation of this
21		section. For each partial filling, the dispensing
22		pharmacist shall record on the back of the

нв нмs 2013-1299

prescription (or on another appropriate record,
uniformly maintained, and readily retrievable) the
date of the partial filling, quantity dispensed,
remaining quantity authorized to be dispensed, and the
identification of the dispensing pharmacist. The
total quantity of schedule II controlled substances
dispensed in all partial fillings shall not exceed the
total quantity prescribed, nor shall a prescription be
partially filled more than three times after the
initial date of the prescription. Schedule II
controlled substance prescriptions for patients in a
long-term care facility or patients with a medical
diagnosis documenting a terminal illness shall be
valid for a period not to exceed thirty days from the
issue date unless sooner terminated by the
discontinuance of medication.

(j) A prescription for a schedule II controlled substance may be transmitted by the practitioner or the practitioner's agent to a pharmacy by facsimile equipment; provided that the original written, signed prescription is presented to the pharmacist for review prior to the actual dispensing of the controlled substance, except as noted in subsections (k), (l),

HB HMS 2013-1299

17

18

19

20

21

22

11

12

13

14

15

16

17

18

19

20

21

1	and	(m).	The	original	prescription	shall	be	maintained	i .:

- 2 accordance with section 329-36. A prescription for a schedule
- 3 III, IV, or V controlled substance may be transmitted by the
- 4 practitioner or the practitioner's agent to a pharmacy by
- 5 facsimile; provided that:
- 6 (1) The information shall be communicated only between the
 7 prescribing practitioner or the prescriber's
 8 authorized agent and the pharmacy of the patient's
 9 choice. The original prescription shall be maintained
 10 by the practitioner in accordance with section 329-36;
 - (2) The information shall be communicated in a retrievable, recognizable format acceptable to the intended recipient and shall include the physician's oral code designation and the name of the recipient pharmacy;
 - (3) No electronic system, software, or other intervening mechanism or party shall alter the practitioner's prescription, order entry, selection, or intended selection without the practitioner's approval on a per prescription per order basis. Facsimile prescription information shall not be altered by any system,

1		software, or other intervening mechanism or party
2		prior to receipt by the intended pharmacy;
3	(4)	The prescription information processing system shall
4		provide for confidentiality safeguards required by
5	`	federal or state law; and
6	(5)	Prescribing practitioners and pharmacists shall
7		exercise prudent and professional judgment regarding
8		the accuracy, validity, and authenticity of any
9		facsimile prescription information. The facsimile
10		shall serve as the original written prescription for
11		purposes of this section and shall be maintained in
12		accordance with section 329-36.
13	(k)	A prescription prepared in accordance with subsection
14	(g) writt	en for a narcotic listed in schedule II to be
15	compounde	d for the direct administration to a patient by
16	parentera	l, intravenous, intramuscular, subcutaneous, or
17	intraspin	al infusion, but does not extend to the dispensing of
18	oral dosa	ge units of controlled substances, may be transmitted
19	by the pr	actitioner or the practitioner's agent to the pharmacy
20	by facsim	ile. The original prescription shall be maintained by
21	the pract	itioner in accordance with section 329-36. The
22	pharmacis	t shall note on the face of the facsimile prescription



- 1 in red ink "Home Infusion/IV" and this facsimile shall serve as
- 2 the original written prescription for purposes of this section
- 3 and it shall be maintained in accordance with section 329-36.
- 4 (1) A prescription prepared in accordance with subsection
- 5 (g) written for a schedule II substance for a patient enrolled
- 6 in a hospice care program certified or paid for by medicare
- 7 under Title XVIII or a hospice program that is licensed by the
- 8 State may be transmitted by the practitioner or the
- 9 practitioner's agent to the dispensing pharmacy by facsimile.
- 10 The original prescription shall be maintained by the
- 11 practitioner in accordance with section 329-36. The
- 12 practitioner or practitioner's agent shall note on the
- 13 prescription that the patient is a hospice patient. The
- 14 pharmacist shall note on the face of the facsimile prescription
- 15 in red ink "HOSPICE" and this facsimile shall serve as the
- 16 original written prescription for purposes of this section and
- 17 it shall be maintained in accordance with section 329-36.
- 18 (m) A prescription prepared in accordance with subsection
- 19 (g) written for a schedule II controlled substance for a
- 20 resident of a state-licensed long-term care facility may be
- 21 transmitted by the practitioner or the practitioner's agent to
- 22 the dispensing pharmacy by facsimile. The original prescription



1	shall be	maintained by the practitioner in accordance with
2	section 3	29-36. The pharmacist shall note on the face of the
3	facsimile	prescription in red ink "LTCF" and this facsimile
4	shall ser	ve as the original written prescription for purposes of
5	this sect	ion and it shall be maintained in accordance with
6	section 3	29-36.
7	<u>(n)</u>	An electronic prescription for a schedule II, III, IV,
8	or V cont	rolled substance may be electronically transmitted by
9	the pract	itioner to a pharmacy; provided that:
10	(1)	The information shall be communicated only between the
11		prescribing practitioner and the pharmacy of the
12		patient's choice. The electronic prescription shall
13		be maintained by the practitioner in accordance with
14		section 329-36;
15	(2)	The information shall be communicated in a
16		retrievable, recognizable format acceptable to the
17		<pre>intended recipient;</pre>
18	(3)	No electronic system, software, or other intervening
19		mechanism or party shall alter the practitioner's
20		prescription, order entry, selection, or intended
21		selection without the practitioner's approval on a
22		per-prescription, per-order basis. Transmitted



1		prescription information shall not be altered by any
2		electronic system, software, or other intervening
3		mechanism or party prior to receipt by the intended
4		pharmacy;
5	(4)	The prescription information processing system shall
6		provide for confidentiality safeguards required by any
7		applicable federal or state law; and
8	(5)	Prescribing practitioners and pharmacists shall
9		exercise prudent and professional judgment regarding
10		the accuracy, validity, and authenticity of any
11		electronic prescription information."
12	SECT	ION 4. Section 329-42, Hawaii Revised Statutes, is
13	amended by	y amending subsection (a) to read as follows:
14	"(a)	It is unlawful for any person knowingly or
15	intention	ally:
16	(1)	To distribute as a registrant a controlled substance
17		classified in schedule I or II, except pursuant to an
18		order form as required by section 329-37;
19	(2)	To use in the course of the manufacture, distribution,
20		administration, or prescribing of a controlled
21		substance a registration number that is fictitious,

НВ HMS 2013-1299

1		revo	ked, suspended, expired, or issued to another
2		pers	on;
3	(3)	То о	btain or attempt to obtain any controlled
4		subs	tance or procure or attempt to procure the
5		admi	nistration of any controlled substance:
6		(A)	By fraud, deceit, misrepresentation,
7			embezzlement, theft;
8		(B)	By the forgery or alteration of a prescription or
9			of any written order;
10		(C)	By furnishing fraudulent medical information or
11			the concealment of a material fact;
12		(D)	By the use of a false name, patient
13			identification number, or the giving of false
14			address;
15		(E)	By the unauthorized use of a [physician's]
16			<pre>practitioner's oral call-in number; [or]</pre>
17		(F)	By the alteration of a prescription by the
18			addition of future refills;
19		(G)	By the unauthorized use of a practitioner's
20			electronic prescription application; or
21		<u>(H)</u>	By the unauthorized transmission of an electronic
22			prescription;

нв нмs 2013-1299

H.B. NO. 651

(4)	To furnish false or fraudulent material information
	in, or omit any material information from, any
	application, report, or other document required to be
	kept or filed under this chapter, or any record
	required to be kept by this chapter;

- (5) To make, distribute, or possess any punch, die, plate, stone, or other thing designed to print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or device of another or any likeness of any of the foregoing upon any drug or container or labeling thereof so as to render the drug a counterfeit substance;
- (6) To misapply or divert to the person's own use or other unauthorized or illegal use or to take, make away with, or secrete, with intent to misapply or divert to the person's own use or other unauthorized or illegal use, any controlled substance that shall have come into the person's possession or under the person's care as a registrant or as an employee of a registrant who is authorized to possess controlled substances or has access to controlled substances by virtue of the person's employment; or

HB HMS 2013-1299

	JAN 1 9 2013
	INTRODUCED BY: Wella a Ruetti
9	
8	SECTION 6. This Act shall take effect upon its approval.
7	and stricken. New statutory material is underscored.
6	SECTION 5. Statutory material to be repealed is bracketed
5	licensed practitioner."
4	in any other manner without the authorization of the
3	photocopied, electronically transmitted, or reproduced
2	form, whether blank, faxed, computer generated,
1	(7) To make, distribute, possess, or sell any prescription

Report Title:

Electronic Prescriptions; Controlled Substances; Drug Enforcement Administration

Description:

Amends the Uniform Controlled Substances Act in Chapter 329, Hawaii Revised Statutes, by adding definitions consistent with federal law, clarifying the conditions for electronic transmittal of prescriptions, and adding and clarifying violations of prohibited acts.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.